Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer
Jonathan M. Weiss, Martin L. Sos, Danila Seidel et al. · Science Translational Medicine · 2010
Lung cancer remains one of the leading causes of cancer-related death in developed countries. Although lung adenocarcinomas with EGFR mutations or EML4-ALK fusions respond to treatment by epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) inhibition, respectively, squamous cell lung cancer currently lacks therapeutically exploitable genetic alterations. We conducted a systematic search in a set of 232 lung cancer specimens for genetic alterations that were therapeutically amenable and then performed high-resolution gene copy number analyses. We identified frequent and focal fibroblast growth factor receptor 1 (FGFR1) amplification in squamous cell lung cancer (n = 155), but not in other lung cancer subtypes, and, by fluorescence in situ hybridization, confirmed the presence of FGFR1 amplifications in an independent cohort of squamous cell lung cancer samples (22% of cases). Using cell-based screening with the FGFR inhibitor PD173074 in a large (n = 83) panel of lung cancer cell lines, we demonstrated that this compound inhibited growth and induced apoptosis specifically in those lung cancer cells carrying amplified FGFR1. We validated the FGFR1 dependence of FGFR1-amplified cell lines by FGFR1 knockdown and by ectopic expression of an FGFR1-resistant allele (FGFR1(V561M)), which rescued FGFR1-amplified cells from PD173074-mediated cytotoxicity. Finally, we showed that inhibition of FGFR1 with a small molecule led to significant tumor shrinkage in vivo. Thus, focal FGFR1 amplification is common in squamous cell lung cancer and associated with tumor growth and survival, suggesting that FGFR inhibitors may be a viable therapeutic option in this cohort of patients.
Cited by 821 works. doi:10.1126/scitranslmed.3001451
Authors
- Jonathan M. Weiss
- Martin L. Sos
- Danila Seidel
- Martin Peifer
- Thomas Zander
- Johannes M. Heuckmann
- Roland Tillmann Ullrich
- Roopika Menon
- Sebastian H. Maier
- Alex Soltermann
- Holger Moch
- Patrick Wagener
- Florian Fischer
- Stefanie Heynck
- Mirjam Koker
- Jakob Schöttle
- Frauke Leenders
- Franziska Gabler
- Ines Dabow
- Silvia Querings
References
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
- Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
- Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- Patterns of somatic mutation in human cancer genomes
- Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor